Natco Pharma has increased its stake in US-based biotechnology firm eGenesis by investing an additional $14 million. This brings Natco's total investment in eGenesis to $22 million, signalling a strategic focus on advanced therapeutic programmes.
Natco Pharma Invests Additional $14 Million in US Biotech eGenesis
Natco Pharma Limited announced a further investment of US$ 14 million in eGenesis, Inc., a US-based clinical-stage biotechnology company. This new capital infusion brings Natco Pharma's total cumulative investment in eGenesis to US$ 22 million. ## What just happened Natco Pharma, through its subsidiaries NATCO Pharma (Canada) Inc. and NATCO Pharma South Africa Proprietary Limited, has invested an additional US$ 14 million into eGenesis, Inc. This investment is in the form of convertible promissory notes with an 8% annual interest rate. ## Why this matters This move underscores Natco Pharma's strategy to invest in innovative, new-age therapeutic programmes aimed at addressing significant unmet medical needs, particularly in the biotechnology sector. It signals a commitment to science-driven growth and diversification beyond its core oncology and specialty pharmaceuticals business. ## The backstory This latest investment follows an initial US$ 8 million investment made by Natco Pharma in eGenesis in 2024 through preferred stock. The total investment now stands at US$ 22 million. ## What changes now The investment is expected to be completed by September 30, 2026. Natco Pharma has confirmed this transaction is not a related party transaction and does not involve acquiring additional shares at the time of note subscription. ## Risks to watch eGenesis is a pre-revenue company still in the clinical stage, meaning its success is contingent on the outcomes of its research and development, and clinical trials. The long-term financial returns are subject to regulatory approvals and market adoption of its therapeutic solutions. ## Peer comparison eGenesis is focused on transforming organ transplantation using gene editing. Its work in porcine kidney transplants and therapeutic cell transplantation places it in a highly specialized and competitive field within biotechnology. ## Context metrics (time-bound) The latest investment is US$ 14 million, bringing the total cumulative investment to US$ 22 million. The convertible promissory notes carry an 8% interest rate. ## What to track next Investors should closely monitor eGenesis's progress in its clinical trials, key regulatory milestones, and Natco Pharma's overall strategy regarding its investments in early-stage biotechnology firms.
